Data / Research funding / Duchenne/ Becker Muscular Dystrophy
Duchenne/ Becker Muscular Dystrophy: 156 NIH awards ($151.4M) to 72 organizations
156 NIH awards ($151.4M) in the NIH spending category Duchenne/ Becker Muscular Dystrophy, to 72 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
156 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $4,927,507 | May 5, 2010 | August 31, 2025 | VANDENBORNE, KRISTA H | reporter.nih.gov |
| Genetic modifiers of Duchenne Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,704,232 | May 15, 2014 | July 31, 2027 | FLANIGAN, KEVIN M | reporter.nih.gov |
| Dystrophin Replacement | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,349,499 | April 1, 1991 | April 30, 2026 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| Reprogramming and Directed Differentiation of Skeletal Muscle Cells from hPSCs | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,204,262 | September 20, 2013 | June 30, 2028 | PYLE, APRIL D | reporter.nih.gov |
| IND-enabling studies of non-immunogenic gene therapy for ultra-rare DMD patients excluded from dystrophin trials | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $3,161,261 | August 1, 2024 | July 31, 2027 | STEDMAN, HANSELL H | reporter.nih.gov |
| Cardiovascular Consequences of Duchenne and Becker Muscular Dystrophinopathies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,104,268 | September 1, 2021 | August 31, 2027 | WITMAN, MELISSA A.H. | reporter.nih.gov |
| Preclinical studies of pluripotent stem cell-derived myogenic progenitors in non-human primates | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,948,443 | August 6, 2021 | December 31, 2026 | PERLINGEIRO, RITA C. R. | reporter.nih.gov |
| Cytoskeletal Interactions of Dystrophin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,806,646 | July 15, 1994 | July 31, 2026 | ERVASTI, JAMES M | reporter.nih.gov |
| Three-model platform for understanding DMD epigenetic mechanisms and advancing small molecule therapies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,725,938 | February 4, 2021 | December 31, 2026 | MAVES, LISA | reporter.nih.gov |
| Paracrine actions of fibroblasts promote pathologic cardiac myocyte remodeling in Duchenne muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,557,217 | July 1, 2021 | June 30, 2027 | WELC, STEVEN S | reporter.nih.gov |
| Pathogenic Alterations of the 3D Epigenetic Landscape in Dystrophin-Deficient Skeletal Muscles and Reversal by Dystrophin Re-Expression | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,541,743 | August 1, 2009 | May 31, 2027 | PURI, PIER LORENZO | reporter.nih.gov |
| Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,376,851 | September 1, 2020 | July 31, 2026 | KIM, DEOK-HO | reporter.nih.gov |
| A cross-species preclinical platform to enhance the translation of new medicines | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $2,306,784 | December 1, 2023 | November 30, 2026 | GEISSE, NICHOLAS ANDREW | reporter.nih.gov |
| Mechanism of immune response to muscle-directed AAV gene transfer | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,292,756 | May 19, 2023 | April 30, 2028 | HERZOG, ROLAND W. | reporter.nih.gov |
| Cerebellar pathology in the absence of plasticity gating | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,290,342 | July 1, 2021 | April 30, 2026 | PUGH, JASON RICHARD | reporter.nih.gov |
| Activity and therapeutic antagonism of the TP receptor in cardiomyopathy of muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,092,461 | July 1, 2023 | June 30, 2027 | WEST, JAMES D | reporter.nih.gov |
| Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $2,060,218 | June 16, 2022 | May 31, 2024 | DEMONBREUN, ALEXIS R. | reporter.nih.gov |
| Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,054,966 | September 30, 2020 | August 31, 2025 | VILLALTA, SERGIO ARMANDO | reporter.nih.gov |
| Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,025,915 | August 1, 2020 | April 30, 2026 | SPENCER, MELISSA JAN | reporter.nih.gov |
| Evolving High Potency AAV Vectors for Neuromuscular Genome Editing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $1,992,277 | September 10, 2018 | July 31, 2024 | ASOKAN, ARAVIND | reporter.nih.gov |
| Role of Skeletal Muscle Lymphatics in Duchenne Muscular Dystrophy Regulation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,963,162 | May 24, 2022 | April 30, 2027 | MUTHUCHAMY, MARIAPPAN | reporter.nih.gov |
| Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $1,953,245 | April 1, 2015 | August 31, 2026 | WUEBBLES, RYAN DAVID | reporter.nih.gov |
| Interdependency of fibroadipogenic progenitors and extracellular matrix that drive skeletal muscle fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,940,024 | April 5, 2022 | March 31, 2027 | SMITH, LUCAS R | reporter.nih.gov |
| Deciphering the roles of FXR1 in health and myopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,854,831 | August 1, 2022 | July 31, 2026 | GREGORIO, CAROL C | reporter.nih.gov |
| The Role of Lipin1 in Myofiber Stability and Integrity | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,799,008 | July 22, 2021 | May 31, 2027 | REN, HONGMEI | reporter.nih.gov |
| Controllable base editing therapy for DMD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,786,579 | September 1, 2023 | August 31, 2027 | HAN, RENZHI | reporter.nih.gov |
| Ferroptosis in the Heart: Iron Calcium Crosstalk and Compartmentalization | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,751,600 | December 25, 2021 | November 30, 2026 | XIE, LAI-HUA | reporter.nih.gov |
| Mechanisms of mineralocorticoid receptor antagonism on inflammation in muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,726,538 | January 1, 2022 | December 31, 2026 | RAFAEL-FORTNEY, JILL A | reporter.nih.gov |
| Mechanisms of sodium channel clustering at the neuromuscular junction | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,723,360 | January 20, 2020 | December 31, 2029 | RASBAND, MATTHEW N | reporter.nih.gov |
| Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,694,079 | September 23, 2023 | August 31, 2027 | WEISLEDER, NOAH | reporter.nih.gov |
| Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $1,672,364 | February 15, 2016 | August 31, 2022 | HOFFMAN, ERIC P. | reporter.nih.gov |
| Functions of skeletal muscle mineralocorticoid receptor signaling in chronic and acute injury | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,666,931 | April 1, 2018 | August 31, 2029 | RAFAEL-FORTNEY, JILL A | reporter.nih.gov |
| 3D Bioprinted Human Model of Duchenne Muscular Dystrophy (DMD) Cardiomyopathy to Study Disease Progression with Imposed Force and Precise Gene Editing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,651,448 | July 1, 2023 | April 30, 2028 | KAMDAR, FORUM D | reporter.nih.gov |
| CRISPR editing therapy for Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,639,600 | July 15, 2023 | June 30, 2028 | DUAN, DONGSHENG | reporter.nih.gov |
| Biomarker Signatures for Duchenne Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $1,617,513 | April 1, 2022 | March 31, 2026 | HATHOUT, YETRIB | reporter.nih.gov |
| Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,576,689 | January 23, 2024 | December 31, 2028 | SOSLOW, JONATHAN HARVEY | reporter.nih.gov |
| Dynamic Biomaterial Design to Probe the Cellular Response to Fibrotic Stiffening | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,574,063 | August 15, 2021 | July 31, 2025 | BLAU, HELEN M | reporter.nih.gov |
| Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,559,533 | September 25, 2023 | July 31, 2027 | KYBA, MICHAEL | reporter.nih.gov |
| Development of early metabolic imaging biomarkers for muscular dystrophy and cardiomyopathy in patients | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,514,698 | June 15, 2024 | April 30, 2028 | PARK, JAE MO | reporter.nih.gov |
| Molecular mechanisms of telomere function in muscle stem cells | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,514,489 | April 1, 2020 | April 28, 2025 | MOURKIOTI, FOTEINI | reporter.nih.gov |
| Vascularized kidney organoids on chip for efficacy and toxicity testing of somatic genome editing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,427,720 | September 10, 2019 | June 30, 2025 | MORIZANE, RYUJI | reporter.nih.gov |
| Understanding the Mechanisms of Fibrosis in Muscular Dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,392,499 | July 12, 2023 | May 31, 2028 | HAMMERS, DAVID W | reporter.nih.gov |
| Connexin 43: a new player in Duchenne muscular dystrophy associated cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,392,382 | July 15, 2024 | May 31, 2028 | FRAIDENRAICH, DIEGO | reporter.nih.gov |
| IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients | NIH | National Heart, Lung, and Blood Institute | 2024 | $1,358,179 | September 20, 2024 | September 19, 2025 | STRANGE, KEVIN | reporter.nih.gov |
| Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,340,252 | January 18, 2023 | December 31, 2027 | FLANIGAN, KEVIN M | reporter.nih.gov |
| Ciliary Hedgehog signaling during adult tissue repair and disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,327,925 | April 1, 2022 | March 31, 2027 | KOPINKE, DANIEL | reporter.nih.gov |
| Targeting Nitrate-Nitrite-NO pathway for Ameliorating Muscle and Bone Comorbidities in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,321,811 | September 15, 2020 | August 31, 2025 | LI, HONGSHUAI | reporter.nih.gov |
| Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,321,604 | August 1, 2019 | April 30, 2027 | YOUNG, COURTNEY S | reporter.nih.gov |
| Optimizing Gene Therapy for Respiratory Insufficiency in Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,258,938 | July 29, 2024 | June 30, 2028 | ELMALLAH, MAI | reporter.nih.gov |
| Targeting myocardial fibrosis with a novel noncoding RNA in Duchenne muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,153,657 | January 12, 2024 | December 31, 2028 | ROGERS, RUSSELL | reporter.nih.gov |
| Modulation of Jagged1/Pitpna in DMD as a means of therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $1,152,624 | April 1, 2014 | July 31, 2025 | KUNKEL, LOUIS M | reporter.nih.gov |
| Role of FGF21 in DMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,142,423 | August 7, 2024 | June 30, 2029 | LI, HONGSHUAI | reporter.nih.gov |
| Multi-coil multi-nuclear add-on system for clinical field strength NMR-based biomarker detection for Duchenne Muscular Dystrophy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,110,294 | April 1, 2020 | December 31, 2024 | MCDOUGALL, MARY PRESTON | reporter.nih.gov |
| Modulating the adaptive immune response to enhance the efficiency of in vivo gene editing in muscle | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,074,756 | July 1, 2024 | June 30, 2029 | SERWOLD, THOMAS F | reporter.nih.gov |
| Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,068,101 | May 1, 2024 | March 31, 2028 | MONTES, JACQUELINE | reporter.nih.gov |
| Smad8 is a driver of Duchenne muscular dystrophy pathology via myomiR repression | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,050,867 | December 1, 2020 | November 30, 2026 | LOPEZ, MICHAEL ALONZO | reporter.nih.gov |
| In vivo role of the fibroblast in muscular dystrophy-Renewal | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,026,671 | April 1, 2018 | June 30, 2030 | VANHOUTTE, DAVY | reporter.nih.gov |
| Developing co-stimulatory blockade as a therapeutic strategy for Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,023,750 | September 15, 2019 | June 30, 2025 | TIDBALL, JAMES G | reporter.nih.gov |
| Structure-Function Analysis of Sarcospan | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $1,015,872 | September 24, 2001 | May 31, 2025 | CROSBIE, RACHELLE HOPE | reporter.nih.gov |
| Technologies to enable safe and effective gene editing in skeletal muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,011,048 | September 10, 2024 | July 31, 2029 | WANG, ERIC T | reporter.nih.gov |
| Development and optimization of skeletal muscle delivery vehicles | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $997,591 | July 8, 2024 | May 31, 2029 | MILLAY, DOUGLAS PAUL | reporter.nih.gov |
| Targeting PTEN to ameliorate muscular dystrophy in a mouse model | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $989,224 | January 27, 2022 | December 31, 2024 | KUANG, SHIHUAN | reporter.nih.gov |
| Mechanisms of corticosteroids in dystrophic cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $968,546 | August 1, 2020 | November 1, 2023 | HEIER, CHRISTOPHER RYAN | reporter.nih.gov |
| Origins and Functions of Intramuscular Macrophages in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $935,104 | August 5, 2019 | February 29, 2024 | ZHOU, LAN | reporter.nih.gov |
| Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $914,016 | May 1, 2018 | April 30, 2024 | METZGER, JOSEPH MARK | reporter.nih.gov |
| Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $840,961 | September 1, 2023 | August 31, 2025 | ODOM, GUY LEARY | reporter.nih.gov |
| Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2021 | $807,541 | September 1, 2020 | July 31, 2022 | KIM, DEOK-HO | reporter.nih.gov |
| Molecular basis of telomere dysfunction in cardiac dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $802,230 | August 1, 2019 | June 30, 2024 | MOURKIOTI, FOTEINI | reporter.nih.gov |
| Electrical impedance myography in an animal model | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $766,280 | August 1, 2007 | July 31, 2024 | RUTKOVE, SEWARD B. | reporter.nih.gov |
| Mechanisms of corticosteroids in dystrophic cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $758,329 | August 1, 2020 | July 31, 2025 | HEIER, CHRISTOPHER RYAN | reporter.nih.gov |
| Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | NIH | Office of the Director, National Institutes of Health | 2021 | $752,426 | April 1, 2015 | August 31, 2023 | BURKIN, DEAN J. | reporter.nih.gov |
| Targeting Pannexin 1 as a Novel Mechanism for Arrhythmia and Fibrosis in Duchenne Cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $741,945 | January 7, 2021 | December 31, 2025 | RAUCCI, FRANK J | reporter.nih.gov |
| Understanding regulation of pediatric regenerative myogenesis and its implication for muscle disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $692,292 | April 1, 2025 | March 31, 2030 | NOVAK, JAMES STEPHEN | reporter.nih.gov |
| Expression of dystrophins with enhanced function | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $671,240 | January 22, 2025 | December 31, 2029 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| A MIR-486/DOCK3 SIGNALING AXIS MODULATES DYSTROPHIN-DEFICIENT PATHOLOGY | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $653,868 | August 17, 2018 | May 31, 2024 | ALEXANDER, MATTHEW SCOTT | reporter.nih.gov |
| Readthrough of disease-causing nonsense mutations by targeted selenocysteine recoding | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $644,779 | September 20, 2022 | August 31, 2025 | REGEV, ODED | reporter.nih.gov |
| Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $616,017 | June 16, 2022 | May 31, 2027 | DEMONBREUN, ALEXIS R. | reporter.nih.gov |
| Ferroptosis in the Heart: Iron Calcium Crosstalk and Compartmentalization | NIH | National Heart, Lung, and Blood Institute | 2022 | $603,528 | December 25, 2021 | November 30, 2022 | XIE, LAI-HUA | reporter.nih.gov |
| Deciphering the roles of FXR1 in health and myopathy | NIH | National Heart, Lung, and Blood Institute | 2022 | $601,489 | August 1, 2022 | April 30, 2023 | GREGORIO, CAROL C | reporter.nih.gov |
| MR Assessment of the effect of nNOS on Bioenergetics and Microvascular Function in Becker and Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $599,496 | September 15, 2025 | August 31, 2030 | FORBES, SEAN C | reporter.nih.gov |
| Whole body single AAV microgene in canine DMD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $598,651 | September 1, 2015 | April 30, 2030 | DUAN, DONGSHENG | reporter.nih.gov |
| Molecular Mechanisms of Dystrophic Cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $568,465 | August 1, 2019 | May 31, 2024 | WANG, DA-ZHI | reporter.nih.gov |
| Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $536,800 | September 15, 2023 | August 31, 2026 | TAIVASSALO, TANJA | reporter.nih.gov |
| Preclinical development of DMD exon 44 skipping using AAV.U7snRNA: a versatile tool that can help 6-12% of DMD patient | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $519,166 | August 8, 2025 | January 31, 2027 | FLANIGAN, KEVIN M | reporter.nih.gov |
| MOLECULAR MECHANISMS OF DYSTROPHIC CARDIOMYOPATHY | NIH | National Heart, Lung, and Blood Institute | 2021 | $518,390 | August 1, 2019 | August 30, 2021 | WANG, DA-ZHI | reporter.nih.gov |
| Assembly of the Dystrophin-Glycoprotein Complex | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $508,614 | April 19, 1997 | March 31, 2022 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| Innovative Approaches to Treat Duchenne Muscular Dystrophy Using iPSC-Derived Muscle Progenitors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $499,954 | April 1, 2016 | March 31, 2023 | TANG, YAO LIANG | reporter.nih.gov |
| Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $499,300 | September 1, 2025 | July 31, 2028 | YOUNG, COURTNEY S | reporter.nih.gov |
| Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $499,207 | August 1, 2019 | March 31, 2023 | YOUNG, COURTNEY S | reporter.nih.gov |
| TRPC6 inhibition therapy to rescue cardiac muscle dysfunction in muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $498,000 | March 18, 2024 | February 28, 2027 | LIN, BRIAN LEEI | reporter.nih.gov |
| Physiologic stress in advanced tissue culture models of cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $492,156 | December 15, 2022 | November 30, 2027 | FULLENKAMP, DOMINIC EDWARD | reporter.nih.gov |
| Development of Utrophin Site Blocking Oligos (SBOs) to Treat Duchenne Muscular Dystrophy (DMD) | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $490,761 | August 18, 2023 | July 31, 2026 | KHURANA, TEJVIR S | reporter.nih.gov |
| Contribution of ribosome specialization to the pathophysiology of muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $487,764 | November 1, 2023 | October 31, 2026 | WEN, YUAN | reporter.nih.gov |
| Gene Therapy Design Principles for Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $476,731 | September 1, 2023 | August 31, 2028 | EGUCHI, ASUKA | reporter.nih.gov |
| Progressive loading of a human dystrophic cardiomyopathy 3D model to mimic disease and evaluate therapeutic | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $465,872 | September 1, 2022 | August 31, 2025 | KAMDAR, FORUM D | reporter.nih.gov |
| PAR-18-953 (ASCOT-DMD) | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $456,600 | August 15, 2021 | May 31, 2025 | THANGARAJH, MATHULA | reporter.nih.gov |
| CHERISH (duCHennE caRdiomyopathy mItigation Sglt2 inHibitor) | NIH | National Heart, Lung, and Blood Institute | 2025 | $444,838 | September 4, 2025 | August 31, 2027 | MARKHAM, LARRY W. | reporter.nih.gov |
| Development of myotropic human bocavirus vectors for gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $440,675 | June 12, 2024 | April 30, 2027 | QIU, JIANMING | reporter.nih.gov |
| Development of anti-LTBP4 as a biologic to treat Limb Girdle Muscular Dystrophy 2C | NIH | National Center for Advancing Translational Sciences | 2025 | $440,000 | August 1, 2025 | July 31, 2027 | DEMONBREUN, ALEXIS R. | reporter.nih.gov |
| Structure-based antisense therapeutics targeting dystrophin exons 44 and 45 for Duchenne Muscular Dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $433,125 | September 1, 2024 | August 31, 2026 | GUO, FENG | reporter.nih.gov |
| Clinical Trial Readiness for Monitoring Muscle Inflammation in Duchenne Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2023 to 2024 | $429,645 | August 1, 2023 | June 30, 2026 | HOFFMAN, ERIC P. | reporter.nih.gov |
| Brain Connectivity Signatures of Behavior and Cognition in Duchenne Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $429,000 | September 30, 2021 | March 31, 2025 | JOSHI, SHANTANU H. | reporter.nih.gov |
| Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $414,187 | September 1, 2021 | July 31, 2024 | KIM, SARAH | reporter.nih.gov |
| Foundations for a Phase 1 Clinical Trial ofCell-based Therapy for Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $409,200 | July 15, 2022 | June 30, 2024 | KANG, PETER B. | reporter.nih.gov |
| NADPH Oxidase and Autophagic Dysfunction in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $409,087 | August 1, 2012 | July 31, 2023 | RODNEY, GEORGE G | reporter.nih.gov |
| Therapeutic targeting of miR-128-1 in Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $401,250 | August 1, 2022 | July 31, 2024 | NAAR, ANDERS M | reporter.nih.gov |
| Connexin 43: a new player in Duchenne muscular dystrophy associated cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 | $394,768 | September 1, 2018 | June 30, 2023 | FRAIDENRAICH, DIEGO | reporter.nih.gov |
| Internal and External Validation of a Porcine Dystrophinopathy Model | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $382,500 | September 1, 2021 | August 31, 2023 | SELSBY, JOSHUA T | reporter.nih.gov |
| Elucidation of the role of human genetic factors underlying viral myocarditis susceptibility | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $380,676 | July 6, 2018 | June 30, 2023 | KONTOROVICH, AMY R. | reporter.nih.gov |
| Development of optimized AAVrh74 vectors for gene therapy of muscular dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $377,143 | January 25, 2023 | December 31, 2025 | SRIVASTAVA, ARUN | reporter.nih.gov |
| Genetic repair of muscular degeneration associated with Duchenne muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $375,393 | June 1, 2016 | August 31, 2025 | VIDAL GADEA, ANDRES GABRIEL | reporter.nih.gov |
| Disease Modeling of Skeletaland Cardiac Muscle in DMD/BMD using Patient-Specific iPS Cells | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $375,100 | March 7, 2022 | February 29, 2024 | PERLINGEIRO, RITA C. R. | reporter.nih.gov |
| Systemic delivery of muscle stem cell for muscle disease therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $375,100 | May 1, 2022 | April 30, 2024 | ASAKURA, ATSUSHI | reporter.nih.gov |
| Targeting vascular endothelium for muscular dystrophy therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $373,065 | April 1, 2021 | March 31, 2024 | ASAKURA, ATSUSHI | reporter.nih.gov |
| N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $372,350 | March 6, 2023 | August 31, 2026 | DEY, BIJAN K | reporter.nih.gov |
| Micro-laminin Gene Therapy for MDC1A | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $370,986 | April 15, 2021 | March 31, 2024 | MARTIN, PAUL TAYLOR | reporter.nih.gov |
| Interrogating functional and molecular properties of PAX7+ putative skeletal muscle stem/progenitor cells derived from human iPSCs of healthy donors and Duchenne muscular dystrophy patients | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $348,502 | March 1, 2017 | February 28, 2022 | LEE, GABSANG | reporter.nih.gov |
| PKR as a therapeutic target for muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $347,447 | July 29, 2022 | June 30, 2025 | SELSBY, JOSHUA T | reporter.nih.gov |
| Bioengineering of phage-derived particles as a discovery platform for muscle gene therapy | NIH | National Center for Advancing Translational Sciences | 2023 | $334,571 | September 1, 2023 | August 31, 2024 | TSEDEV, UYANGA | reporter.nih.gov |
| Computational prediction of RNA splicing defects and rescue by small-molecule therapeutics | NIH | National Institute of General Medical Sciences | 2023 | $333,843 | September 6, 2023 | December 31, 2023 | XIONG, HAISHAN | reporter.nih.gov |
| Targeting PTEN to ameliorate muscular dystrophy in a mouse model | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $319,770 | January 27, 2022 | December 31, 2027 | KUANG, SHIHUAN | reporter.nih.gov |
| Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $311,250 | September 1, 2024 | August 31, 2026 | YOUNG, COURTNEY S | reporter.nih.gov |
| Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $306,872 | September 1, 2024 | July 31, 2025 | GREENBERG, MILTON L | reporter.nih.gov |
| Ankle contractures in muscular dystrophy: mechanisms and tissue adaptations | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $305,000 | August 1, 2024 | July 31, 2026 | BARNARD, ALISON M | reporter.nih.gov |
| Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $302,500 | September 1, 2025 | August 31, 2027 | YOUNG, COURTNEY S | reporter.nih.gov |
| Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $295,294 | September 1, 2023 | August 31, 2025 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| Translational development of novel CRISPR approach to treat genomic duplications | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $275,651 | August 1, 2023 | July 31, 2025 | LEK, MONKOL | reporter.nih.gov |
| Pilot Trial of Vamorolone for the Treatment of Becker Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $271,230 | July 13, 2020 | June 30, 2025 | CLEMENS, PAULA R | reporter.nih.gov |
| TRPC6 inhibition therapy to rescue cardiac muscle dysfunction in muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $260,660 | January 1, 2022 | December 31, 2023 | LIN, BRIAN LEEI | reporter.nih.gov |
| A Musculoskeletal Simulation Framework for In Silico Design and Optimization of a Soft Exosuit for Children with Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2021 | $253,606 | July 15, 2021 | July 14, 2022 | PICKLE, NATHANIEL | reporter.nih.gov |
| Microtubule acetylation is a novel target in Duchenne muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $245,862 | June 10, 2021 | May 31, 2023 | CAVALCANTE JOCA, HUMBERTO | reporter.nih.gov |
| Caspase-mediated nuclear pore complex trimming in myogenesis and muscular dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $237,501 | February 1, 2023 | November 30, 2025 | CHO, UKRAE | reporter.nih.gov |
| Dystrophin as a novel regulator of the circadian clock in skeletal muscle and the brain | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $236,566 | December 23, 2024 | November 30, 2026 | ALEXANDER, MATTHEW SCOTT | reporter.nih.gov |
| Contribution of ribosome specialization to the pathophysiology of muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $233,940 | August 17, 2022 | October 31, 2023 | WEN, YUAN | reporter.nih.gov |
| Exploration of developmental brain abnormalities in mouse models of Duchenne muscular dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $181,810 | March 3, 2021 | March 2, 2025 | ARREGUIN, ANDREA JASMINE | reporter.nih.gov |
| A Novel Technology for Full-Length Gene Replacement Therapy of Duchenne Muscular Dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $167,855 | February 1, 2022 | June 11, 2025 | HSU, RYAN HON HEAN | reporter.nih.gov |
| Understanding the Transcriptional Networks and Physiologic Adaptations Governing the Clinical Manifestations of Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $152,942 | July 27, 2020 | July 26, 2024 | GARAY, BAYARDO ISIDORE | reporter.nih.gov |
| Altered nucleus-cytoskeleton coupling in dystrophic muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $148,067 | January 20, 2023 | March 31, 2025 | IYER, SHAMA RAJAN | reporter.nih.gov |
| Caspase-mediated nuclear pore complex trimming in myogenesis and muscular dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $130,976 | February 1, 2023 | December 31, 2023 | CHO, UKRAE | reporter.nih.gov |
| Spatiotemporal and Deep Learning Analysis of Cardiac Imaging for Predictive Risk Stratification in Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $130,736 | August 5, 2022 | August 4, 2026 | EARL, CONNER | reporter.nih.gov |
| Understanding and regulating skeletal muscle progenitor and stem cell states through metabolic and epigenetic modulation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $126,024 | July 1, 2021 | June 30, 2024 | CHIEN, PEGGIE JANE | reporter.nih.gov |
| Altered nucleus-cytoskeleton coupling in dystrophic muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $103,412 | July 5, 2019 | June 14, 2022 | IYER, SHAMA RAJAN | reporter.nih.gov |
| CRISPR therapy in the canine DMD model | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $99,608 | September 20, 2022 | August 31, 2023 | DUAN, DONGSHENG | reporter.nih.gov |
| Contribution of hydrogen sulfide to Duchenne muscular dystrophy pathophysiology | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $93,520 | August 1, 2024 | May 1, 2027 | FALLON, KATHERINE SAGE | reporter.nih.gov |
| Spatiotemporal and Deep Learning Analysis of Cardiac Imaging for Predictive Risk Stratification in Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $89,498 | August 5, 2022 | March 31, 2024 | EARL, CONNER | reporter.nih.gov |
| Improving cell membrane repair to treat muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $84,694 | August 1, 2022 | July 31, 2024 | LOPEZ PEREZ, MIGUEL AARON | reporter.nih.gov |
| Development of Muscle Optimized Non-viral Gene Editors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $75,520 | December 1, 2025 | November 30, 2028 | POUKALOV, KERIL | reporter.nih.gov |
| Abnormalities in postnatal brain development as a feature of congenital muscular dystrophies | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $71,238 | December 15, 2020 | December 14, 2021 | COLOGNATO, HOLLY A | reporter.nih.gov |
| Muscle-Specific CRISPR/Cas9 Exon Skipping for Duchenne Muscular Dystrophy Therapeutics | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $66,236 | September 1, 2023 | August 31, 2025 | KRAUS, CAROLYN | reporter.nih.gov |
| Identifying the interactions between fibro-adipogenic progenitors and the extracellular matrix in skeletal muscle fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $60,305 | August 1, 2023 | November 30, 2024 | LOOMIS, TARYN | reporter.nih.gov |
| Micropatterned surfaces for modeling muscular dystrophy-associated cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $56,082 | August 1, 2020 | March 31, 2022 | FULLENKAMP, DOMINIC EDWARD | reporter.nih.gov |
| Investigating the role of FGF21 in bone homeostasis in Duchenne Muscular Dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $46,138 | May 1, 2025 | April 30, 2029 | HURLEY-NOVATNY, AMELIA CHARLOTTE | reporter.nih.gov |
| Role of Connexin43 in the heart and skeletal muscle in a model for Duchenne muscular dystrophy symptomatic carriers | NIH | National Heart, Lung, and Blood Institute | 2022 | $40,959 | September 1, 2020 | August 31, 2023 | NOUET, JULIE | reporter.nih.gov |
| Role of Connexin43 in the heart and skeletal muscle in a model for Duchenne muscular dystrophy symptomatic carriers | NIH | National Heart, Lung, and Blood Institute | 2021 | $40,243 | September 1, 2020 | August 31, 2022 | NOUET, JULIE | reporter.nih.gov |
| Using collagenase to target collagen architecture in fibrotic skeletal muscle to reduce stiffness and promote tissue regeneration. | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $28,047 | May 1, 2024 | November 15, 2024 | WOHLGEMUTH, ROSS PAUL | reporter.nih.gov |
| New Directions in Biology and Disease of Skeletal Muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $10,000 | September 1, 2020 | February 28, 2022 | MCNALLY, ELIZABETH M | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of Florida | Gainesville, FL | 9 | $10.9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 11 | $10.6 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 7 | $8.3 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 5 | $7.2 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 4 | $6 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 4 | $5.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 4 | $5.4 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 4 | $3.8 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 6 | $3.7 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 2 | $3.7 million | 0 | $0 |
| Duke University | Durham, NC | 3 | $3.6 million | 0 | $0 |
| Ohio State University | Columbus, OH | 3 | $3.5 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 3 | $3.2 million | 0 | $0 |
| University of Delaware | Newark, DE | 1 | $3.1 million | 0 | $0 |
| Myogene Bio, LLC | San Diego, CA | 5 | $2.9 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 1 | $2.7 million | 0 | $0 |
| Strykagen Corporation | Reno, NV | 2 | $2.7 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 1 | $2.5 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 2 | $2.5 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 3 | $2.5 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 3 | $2.3 million | 0 | $0 |
| Curi Bio INC | Seattle, WA | 1 | $2.3 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 1 | $2.3 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 2 | $2.2 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 2 | $2.1 million | 0 | $0 |
| SUNY at Binghamton | Binghamton, NY | 2 | $2 million | 0 | $0 |
| University of California at Davis | Davis, CA | 3 | $2 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 2 | $2 million | 0 | $0 |
| Myofinity Biosciences INC | Boston, MA | 2 | $2 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 1 | $2 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 3 | $2 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 3 | $1.9 million | 0 | $0 |
| Wright State University | Dayton, OH | 1 | $1.8 million | 0 | $0 |
| Reveragen Biopharma, Inc. | Rockville, MD | 1 | $1.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 2 | $1.7 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 2 | $1.7 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 2 | $1.6 million | 0 | $0 |
| Stanford University | Stanford, CA | 1 | $1.6 million | 0 | $0 |
| Myogenica Inc. | Saint Paul, MN | 1 | $1.6 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 1 | $1.4 million | 0 | $0 |
| Revidia Therapeutics, INC | Ellsworth, ME | 1 | $1.4 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 1 | $1.2 million | 0 | $0 |
| Texas A&M Engineering Experiment Station | College Station, TX | 1 | $1.1 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 2 | $1.1 million | 0 | $0 |
| Joslin Diabetes Center | Boston, MA | 1 | $1.1 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 1 | $1.1 million | 0 | $0 |
| Rbhs-New Jersey Medical School | Newark, NJ | 3 | $1 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 1 | $935,104 | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 1 | $766,280 | 0 | $0 |
| Iowa State University | Ames, IA | 2 | $729,947 | 0 | $0 |
| University of Kentucky | Lexington, KY | 2 | $721,704 | 0 | $0 |
| New York University | New York, NY | 1 | $644,779 | 0 | $0 |
| University of Arizona | Tucson, AZ | 1 | $601,489 | 0 | $0 |
| University of South Florida | Tampa, FL | 1 | $568,465 | 0 | $0 |
| Augusta University | Augusta, GA | 1 | $499,954 | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 1 | $498,000 | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 1 | $440,675 | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 1 | $401,250 | 0 | $0 |
| Board of Trustees of Illinois State University | Normal, IL | 1 | $375,393 | 0 | $0 |
| SUNY at Albany | Albany, NY | 1 | $372,350 | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 2 | $349,274 | 0 | $0 |
| Gensaic, Inc. | Lexington, MA | 1 | $334,571 | 0 | $0 |
| Panorama Medicine, Inc. | Philadelphia, PA | 1 | $333,843 | 0 | $0 |
| Vivreon Biosciences, LLC | San Diego, CA | 1 | $306,872 | 0 | $0 |
| Salk Institute for Biological Studies | La Jolla, CA | 2 | $298,831 | 0 | $0 |
| Gigamune, Inc. | San Francisco, CA | 1 | $295,294 | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 1 | $271,230 | 0 | $0 |
| CFD Research Corporation | Huntsville, AL | 1 | $253,606 | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 2 | $253,048 | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 1 | $237,501 | 0 | $0 |
| Marymount University | Arlington, VA | 1 | $148,067 | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 1 | $66,236 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 69 | $33,696,947 | 0 | $0 |
| 2024 | 77 | $35,693,489 | 0 | $0 |
| 2023 | 80 | $30,167,051 | 0 | $0 |
| 2022 | 73 | $27,991,854 | 0 | $0 |
| 2021 | 60 | $23,850,768 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.